1932
0
  1. Home
  2. A-Z Publications
  3. Annual Review of Cancer Biology
  4. Volume 3, 2019
  5. Article

Annual Review of Cancer Biology

Volume 3, 2019

Targeting Therapies for the p53 Protein in Cancer Treatments

Abstract

Half of all human cancers contain mutations, and in many other cancers, the function of the p53 protein is compromised. The diversity of these mutations and phenotypes presents a challenge to the development of drugs that target p53 mutant cancer cells. This review describes the rationale for many different approaches in the development of p53 targeted therapies: () viruses and gene therapies, () increased levels and activity of wild-type p53 proteins in cancer cells, () p53 protein gain-of-function inhibitors, () p53 protein loss-of-function structural correctors, () mutant p53 protein synthetic lethal drugs interfering with the p53 pathway, and () cellular immune responses to mutant p53 protein antigens. As these types of therapies are developed, tested, and evaluated, the best of them will have a significant impact upon cancer treatments and possibly prevention.

Keyword(s): drugs that target p53, immunological detection of p53 mutant antigens, mutant p53 proteins, p53 pathway functions, p53 structure, synthetic lethal drugs
Loading

Article metrics loading...

/content/journals/10.1146/annurev-cancerbio-030518-055455
2019-03-04
2025-04-26
Loading full text...

Full text loading...

/deliver/fulltext/cancerbio/3/1/annurev-cancerbio-030518-055455.html?itemId=/content/journals/10.1146/annurev-cancerbio-030518-055455&mimeType=html&fmt=ahah

Literature Cited

  1. Ablain J, Poirot B, Esnault C, Lehmann-Che J, Thé H 2016. p53 as an effector or inhibitor of therapy response. Cold Spring Harb. Perspect. Med. 6:1a026260
     [Google Scholar]
  2. Achatz MI, Zambetti GP 2016. The inherited p53 mutation in the Brazilian population. Cold Spring Harb. Perspect. Med. 6:12a026195
     [Google Scholar]
  3. Alexandrova EM, Yallowitz AR, Li D, Xu S, Schulz R et al. 2015. Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment. Nature 523:7560352–56
     [Google Scholar]
  4. Aylon Y, Oren M 2016. The paradox of p53: What, how, and why. Cold Spring Harbor Perspect. Med 6:10a026328
     [Google Scholar]
  5. Baker SJ, Fearon ER, Nigro JM, Hamilton SR, Preisinger AC et al. 1989. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 244:4901217–21
     [Google Scholar]
  6. Balachandran VP, Łuksza M, Zhao JN, Makarov V, Moral JA et al. 2017. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature 551:7681512–16
     [Google Scholar]
  7. Baldwin A, Grueneberg DA, Hellner K, Sawyer J, Grace M et al. 2010. Kinase requirements in human cells: V. Synthetic lethal interactions between p53 and the protein kinases SGK2 and PAK3. PNAS 107:2812463–68
     [Google Scholar]
  8. Baugh EH, Ke H, Levine AJ, Bonneau RA, Chan CS 2018. Why are there hotspot mutations in the TP53 gene in human cancers. Cell Death Differ 25:154–60
     [Google Scholar]
  9. Blanden AR, Yu X, Wolfe AJ, Gilleran JA, Augeri DJ et al. 2015. Synthetic metallochaperone ZMC1 rescues mutant p53 conformation by transporting zinc into cells as an ionophore. Mol. Pharmacol. 87:825–31
     [Google Scholar]
  10. Bossi G, Lapi E, Strano S, Rinaldo C, Blandino G et al. 2006. Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression. Oncogene 25:304–9
     [Google Scholar]
  11. Bouaoun L, Sonkin D, Ardin M, Hollstein M, Byrnes G et al. 2016. TP53 variations in human cancers: new lessons from the IARC TP53 database and genomics data. Hum. Mutat. 37:9865–76
     [Google Scholar]
  12. Brachmann RK, Yu K, Eby Y, Pavletich NP, Boeke JD 1998. Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations. EMBO J 17:1847–59
     [Google Scholar]
  13. Bromley D, Bauer MR, Fersht AR, Daggett V 2016. An in silico algorithm for identifying stabilizing pockets in proteins: test case, the Y220C mutant of the p53 tumor suppressor protein. Protein Eng. Des. Sel. 29:9377–90
     [Google Scholar]
  14. Buzek J, Latonen L, Kurki S, Peltonen K, Laiho M 2002. Redox state of tumor suppressor p53 regulates its sequence-specific DNA binding in DNA-damaged cells by cysteine 277. Nucleic Acids Res 30:112340–48
     [Google Scholar]
  15. Bykov VJN, Wiman KG 2014. Mutant p53 reactivation by small molecules makes its way to the clinic. FEBS Lett 588:162622–27
     [Google Scholar]
  16. Chen J, Lin J, Levine AJ 1995. Regulation of transcription functions of the p53 tumor suppressor by the mdm-2 oncogene. Mol. Med. 1:142–52
     [Google Scholar]
  17. Cho Y, Gorina S, Jeffrey PD, Pavletich NP 1994. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265:5170346–55
     [Google Scholar]
  18. DeLeo AB, Jay G, Appella E, Dubois GC, Law LW et al. 1979. Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. PNAS 76:52420–24
     [Google Scholar]
  19. Demidenko ZN, Korotchkina LG, Gudkov AV, Blagosklonny MV, Pardee A 2010. Paradoxical suppression of cellular senescence by p53. PNAS 107:219660–64
     [Google Scholar]
  20. Dittmer D, Pati S, Zambetti G, Chu S, Teresky AK 1993. Gain of function mutations in p53. Nat. Genet. 4:42–46
     [Google Scholar]
  21. Duffy MJ, Synnott NC, Crown J 2016. p53 in cancer: Ready for therapeutic targeting. Transl. Cancer Res. 5:6627–31
     [Google Scholar]
  22. Eldar A, Rozenberg H, Diskin-Posner Y, Rohs R, Shakked Z 2013. Structural studies of p53 inactivation by DNA-contact mutations and its rescue by suppressor mutations via alternative protein–DNA interactions. Nucleic Acids Res 41:188748–59
     [Google Scholar]
  23. Eliyahu D, Michalovitz D, Eliyahu S, Pinhasi-Kimhi O, Oren M 1989. Wild-type p53 can inhibit oncogene-mediated focus formation. PNAS 86:228763–67
     [Google Scholar]
  24. Finlay CA, Hinds PW, Levine AJ 1989. The p53 proto oncogene can act as a suppressor of transformation. Cell 57:71083–93
     [Google Scholar]
  25. Forster BA, Coffey HA, Morin MJ, Rastinejad 1999. Pharmacological rescue of mutant p53 conformation and function. Science 286:2507–10
     [Google Scholar]
  26. Freed-Pastor WA, Mizuno H, Zhao X, Langerød A, Moon SH et al. 2012. Mutant p53 disrupts mammary acinar morphogenesis via the mevalonate pathway. Cell 148:1–2244–58
     [Google Scholar]
  27. Fridman JS, Lowe SW 2003. Control of apoptosis by p53. Oncogene 22:569030–40
     [Google Scholar]
  28. Hainaut P, Pfeifer GP 2016. Somatic TP53 mutations in the era of genome sequencing. Cold Spring Harb. Perspect. Med. 6:11a026179
     [Google Scholar]
  29. Hanel W, Marchenko N, Xu S, Yu SX, Weng W et al. 2013. Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis. Cell Death Differ 20:7898–909
     [Google Scholar]
  30. Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD et al. 1997. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat. Med. 3:639–45
     [Google Scholar]
  31. Hinds P, Finlay C, Frey A, Levine AJ 1987. Immunological evidence for the association of p53 with a heat shock protein, hsc70, in p53-plus-ras-transformed cell lines. Mol. Cell. Biol. 7:2863–69
     [Google Scholar]
  32. Jiang L, Kon N, Li T, Wang SJ, Su T et al. 2015. Ferroptosis as a p53-mediated activity during tumour suppression. Nature 520:754557–62
     [Google Scholar]
  33. Jin S, Tong T, Fan W, Fan F, Antinore MJ et al. 2002. GADD45-induced cell cycle G2-M arrest associates with altered subcellular distribution of cyclin B1 and is independent of p38 kinase activity. Oncogene 21:578696–704
     [Google Scholar]
  34. Joerger AC, Ang HC, Fersht AR 2006. Structural basis for understanding oncogenic p53 mutations and designing rescue drugs. PNAS 103:4115056–61
     [Google Scholar]
  35. Joerger AC, Ang HC, Veprintsev DB, Blair CM, Fersht AR 2005. Structures of p53 cancer mutants and mechanism of rescue by second-site suppressor mutations. J. Biol. Chem. 280:1616030–37
     [Google Scholar]
  36. Joerger AC, Fersht AR 2010. The tumor suppressor p53: from structures to drug discovery. Cold Spring Harb. Perspect. Biol. 2:619–38
     [Google Scholar]
  37. Karlseder J, Broccoli D, Dai Y, Hardy S, de Lange T 1999. p53- and ATM-dependent apoptosis induced by telomeres lacking TRF2. Science 283:54061321–25
     [Google Scholar]
  38. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW 1991. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51:23, Part 16304–11
     [Google Scholar]
  39. Kastenhuber ER, Lowe SW 2017. Putting p53 in context. Cell 170:1063–78
     [Google Scholar]
  40. Kato S, Han SY, Liu W, Otsuka K, Shibata H et al. 2003. Understanding the function–structure and function–mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. PNAS 100:148424–29
     [Google Scholar]
  41. Kogan S, Carpizo D 2016. Pharmacological targeting of mutant p53. Transl. Cancer Res. 5:6698–706
     [Google Scholar]
  42. Kussie PH, Gorina S, Marechal V, Elenbaas B, Moreau J et al. 1996. Structure of MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274:948–53
     [Google Scholar]
  43. Lambert JM, Gorzov P, Veprintsev DB, Söderqvist M, Segerbäck D 2009. PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell 15:5376–88
     [Google Scholar]
  44. Lane DP, Crawford LV 1979. T antigen is bound to a host protein in SY40-transformed cells. Nature 278:261–63
     [Google Scholar]
  45. Lee MK, Teoh WW, Phang BH, Tong WM, Wang ZQ et al. 2012. Cell-type, dose, and mutation-type specificity dictate mutant p53 functions in vivo. Cancer Cell 22:751–64
     [Google Scholar]
  46. Levine AJ, Lane DP 2010. The P53 Family Cold Spring Harbor, NY: Cold Spring Harb. Lab.
     [Google Scholar]
  47. Levine AJ, Puzio-Kuter A 2010. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 330:60091340–44
     [Google Scholar]
  48. Li D, Marchenko ND, Moll UM 2011. SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis. Cell Death Differ 18:121904–13
     [Google Scholar]
  49. Lin J, Chen J, Elenbaas B, Levine AJ 1994. Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev 8:1235–46
     [Google Scholar]
  50. Linzer DIH, Levine AJ 1979. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 17:43–52
     [Google Scholar]
  51. Liu X, Wilcken R, Joerger AC, Chuckowree IS, Amin J, Spencer J et al. 2013. Small molecule induced reactivation of mutant p53 in cancer cells. Nucleic Acids Res 41:126034–44
     [Google Scholar]
  52. Lozano G, Levine AJ 2016. The p53 Protein: From Cell Regulation to Cancer Cold Spring Harbor, NY: Cold Spring Harb. Lab.
     [Google Scholar]
  53. Łuksza M, Riaz N, Makarov V, Balachandran VP, Hellmann MD et al. 2017. A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy. Nature 551:7681517–20
     [Google Scholar]
  54. Lutzker G, Levine AJ 1996. A functionally inactive p53 protein in embryonal teratocarcinoma cells is activated by DNA damage or cellular differentiation. Nat. Med. 2:804–10
     [Google Scholar]
  55. Ma CX, Cai S, Li S, Ryan CE, Guo Z et al. 2012. Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models. J. Clin. Investig. 122:41541–52
     [Google Scholar]
  56. Maiuri MC, Galluzzi L, Morselli E, Kepp O, Malik SA, Kroemer G 2010. Autophagy regulation by p53. Curr. Opin. Cell Biol. 2:181–85
     [Google Scholar]
  57. Maltzman W, Czyzyk L 1984. UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol. Cell Biol. 4:91689–94
     [Google Scholar]
  58. Marine JC, Jochemsen AG 2016. MDMX (MDM4), a promising target for p53 reactivation therapy and beyond. Cold Spring Harb. Perspect. Med. 6:7a026237
     [Google Scholar]
  59. Martinez LA, Naguibneva I, Lehrmann H, Vervisch A, Tchénio T et al. 2002. Synthetic small inhibiting RNAs: efficient tools to inactivate oncogenic mutations and restore p53 pathways. PNAS 99:2314849–54
     [Google Scholar]
  60. Mathe E, Olivier M, Kato S, Ishioka C, Hainaut P et al. 2006. Computational approaches for predicting the biological effect of p53 missense mutations: a comparison of three sequence analysis based methods. Nucleic Acids Res 34:51317–25
     [Google Scholar]
  61. Menendez D, Shatz M, Resnick MA 2013. Interactions between the tumor suppressor p53 and immune responses. Curr. Opin. Oncol. 25:185–92
     [Google Scholar]
  62. Momand J, Zambetti GP, Olson DC, George D, Levine AJ 1992. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69:1237–45
     [Google Scholar]
  63. Nikolova PV, Wong K-B, DeDecker B, Henckel J, Fersht AR 2000. Mechanism of rescue of common p53 cancer mutations by second-site suppressor mutations. EMBO J 19:3370–78
     [Google Scholar]
  64. Otsuka K, Kato S, Kakudo Y, Mashiko S, Shibata H et al. 2007. The screening of the second-site suppressor mutations of the common p53 mutants. Int. J. Cancer 121:3559–66
     [Google Scholar]
  65. Peng Z, Yu Q, Bao L 2008. The application of gene therapy in China. IDrugs 11:5346–50
     [Google Scholar]
  66. Petitjean A, Achatz MIW, Borresen-Dale AL, Hainaut P, Olivier M 2007.a TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 26:2157–65
     [Google Scholar]
  67. Petitjean A, Mathe E, Kato S, Ishioka S, Tavtigian SV et al. 2007.b Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum. Mutat. 28:6622–29
     [Google Scholar]
  68. Raj N, Attardi LD 2016. The transactivation domains of the p53 protein. See Lozano & Levine 2016 51–68
  69. Sabapathy K, Lane DP 2018. Therapeutic targeting of p53: All mutants are equal, but some mutants are more equal than others. Nat. Rev. Clin. Oncol. 15:113–30
     [Google Scholar]
  70. Sarnow P, Ho YS, Williams J, Levine AJ 1982. Adenovirus E1b 58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular protein in transformed cells. Cell 28:387–94
     [Google Scholar]
  71. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM 1990. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63:1129–36
     [Google Scholar]
  72. Sermeus A, Michiels CC 2011. Reciprocal influence of the p53 and the hypoxic pathways. Cell Death Dis 2:5e164
     [Google Scholar]
  73. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW 1997. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88:5593–602
     [Google Scholar]
  74. Shalem O, Sanjana NE, Zhang F 2015. High-throughput functional genomics using CRISPR-Cas9. Nat. Rev. Genet. 16:5299–311
     [Google Scholar]
  75. Shimada K, Reznik E, Stokes ME, Krishnamoorthy L, Bos PH et al. 2018. Copper-binding small molecule induces oxidative stress and cell-cycle arrest in glioblastoma-patient-derived cells. Cell Chem. Biol. 25:585–94
     [Google Scholar]
  76. Smith ML, Seo YR 2002. p53 regulation of DNA excision repair pathways. Mutagenesis 17:2149–56
     [Google Scholar]
  77. Soussi T. 2000. P53 antibodies in the sera of patients with various types of cancer. Cancer Res 60:1777–88
     [Google Scholar]
  78. Teodoro JG, Evans SK, Green MR 2007. Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome. J. Mol. Med. 85:1175–86
     [Google Scholar]
  79. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F et al. 2004. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303:5659844–48
     [Google Scholar]
  80. Verhaegh GW, Parat MO, Richard MJ, Hainaut P 1998. Modulation of p53 protein conformation and DNA‐binding activity by intracellular chelation of zinc. Mol. Carcinog. 21:3205–14
     [Google Scholar]
  81. Vikhanskaya F, Lee MK, Mazzoletti M, Broggini M, Sabapathy K 2007. Cancer-derived p53 mutants suppress p53-target gene expression—potential mechanism for gain of function of mutant p53. Nucleic Acids Res 35:62093–104
     [Google Scholar]
  82. Vogel C, Kienitz A, Hofmann I, Muller R, Bastians H 2004. Crosstalk of the mitotic spindle assembly checkpoint with p53 to prevent polyploidy. Oncogene 23:6845–53
     [Google Scholar]
  83. Waldman T, Kinzler KW, Vogelstein B 1995. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res 55:225187–90
     [Google Scholar]
  84. Walker KK, Levine AJ 1996. Identification of a novel p53 functional domain that is necessary for efficient growth suppression. PNAS 93:15335–40
     [Google Scholar]
  85. Wang X, Simon R 2013. Identification of potential synthetic lethal genes to p53 using a computational biology approach. BMC Med. Genom. 6:30
     [Google Scholar]
  86. Wei J, Nagy TA, Vilgelm A, Zaika E, Ogden S et al. 2010. Regulation of p53 tumor suppressor by Helicobacter pylori in gastric epithelial cells. Gastroenterology 139:41333–43
     [Google Scholar]
  87. Werness BA, Levine AJ, Howley PM 1990. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248:76–79
     [Google Scholar]
  88. Wu XW, Bayle HJ, Olson D, Levine AJ 1993. The p53-mdm-2 autoregulatory feedback loop. Genes Dev 7:1126–32
     [Google Scholar]
  89. Yu X, Blanden AR, Narayanan S, Jayakumar L, Lubin J et al. 2014. Small molecule restoration of wild type structure and function of mutant p53 using a novel zinc-metalochaperone based mechanism. Oncotarget 5:8879–86
     [Google Scholar]
  90. Yu X, Vazquez A, Levine AJ, Carpizo DR 2012. Allele-specific p53 mutant reactivation. Cancer Cell 21:5614–25
     [Google Scholar]
  91. Zhang Q, Bykov VJN, Wiman KG, Zawacka-Pankau J 2018. APR-246 reactivates mutant p53 by targeting cysteines 124 and 277. Cell Death Dis 9:439
     [Google Scholar]
  92. Zhang Y, Lu H 2009. Signaling to p53: Ribosomal proteins find their way. Cancer Cell 16:5369–77
     [Google Scholar]
  93. Zhu J, Dou Z, Sammons MA, Levine AJ, Berger SL 2016. Lysine methylation represses p53 activity in teratocarcinoma cancer cells. PNAS 113:359822–27
     [Google Scholar]
/content/journals/10.1146/annurev-cancerbio-030518-055455
Loading
  • Article Type: Review Article

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error